UBS AM
URGN icon

UBS AM’s UroGen Pharma URGN Stock Holding History

UBS AM’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2K Sell
874
-46,545
-98% -$1.26M ﹤0.01% 3031
2026
Q1 		$853K Buy
47,419
+47,016
+11,667% +$943K ﹤0.01% 2399
2025
Q4 		$9.44K Buy
+403
New +$8.74K ﹤0.01% 2864
2025
Q2 		– Sell
-4,360,524
Closed -$48.2M – 2721
2025
Q1 		$48.2M Buy
4,360,524
+2,983,368
+217% +$31.8M 0.01% 697
2024
Q4 		$14.7M Buy
1,377,156
+36,084
+3% +$432K ﹤0.01% 1080
2024
Q3 		$17M Buy
1,341,072
+21,072
+2% +$313K ﹤0.01% 1007
2024
Q2 		$22.1M Buy
+1,320,000
New +$18.8M 0.01% 831
2022
Q2 		– Sell
-22,400
Closed -$195K – 2774
2022
Q1 		$195K Hold
22,400
– – ﹤0.01% 2685
2021
Q4 		$213K Hold
22,400
– – ﹤0.01% 2753
2021
Q3 		$377K Hold
22,400
– – ﹤0.01% 2579
2021
Q2 		$342K Hold
22,400
– – ﹤0.01% 2624
2021
Q1 		$436K Hold
22,400
– – ﹤0.01% 2429
2020
Q4 		$404K Hold
22,400
– – ﹤0.01% 2358
2020
Q3 		$432K Buy
22,400
+3,299
+17% +$74.7K ﹤0.01% 2198
2020
Q2 		$499K Sell
19,101
-2,700
-12% -$66K ﹤0.01% 2131
2020
Q1 		$389K Buy
21,801
+5,400
+33% +$146K ﹤0.01% 2069
2019
Q4 		$547K Buy
+16,401
New +$448K ﹤0.01% 2197
2019
Q3 		– Sell
-6,100
Closed -$219K – 2903
2019
Q2 		$219K Hold
6,100
– – ﹤0.01% 2514
2019
Q1 		$225K Buy
+6,100
New +$256K ﹤0.01% 2415

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

UBS AM's URGN Position: Q2 2026 in Review

UBS AM reduced its UroGen Pharma (URGN) stake by 98% in Q2 2026, selling an estimated $1.26M and leaving 874 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3031.

UBS AM first reported a position in URGN in Q1 2019 and has held it in 19 quarters since. The position peaked at $48.2M in Q1 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • UBS AM held 874 shares of UroGen Pharma worth $32.2K as of Q2 2026.
  • UBS AM sold 46,545 UroGen Pharma shares in Q2 2026, an estimated $1.26M.
  • UroGen Pharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3031 holding.
  • UBS AM first reported a position in UroGen Pharma in Q1 2019 and has held it in 19 quarters since.
  • UBS AM's UroGen Pharma position peaked at $48.2M in Q1 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.